WASHINGTON, Sept. 19, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2024 on Tuesday, October 22, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The... Read more
ANDOVER, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) — MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of technologies that transform our world, today announced that MKS President and Chief Executive Officer John T.C. Lee, will be honored as a Pinnacle Award winner, the highest honor given at Read more
WASHINGTON, Sept. 4, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) confirmed its previously issued guidance for the third quarter and full year 2024 ahead of a previously scheduled analyst event. The Company provides forecasted sales only on a non-GAAP core revenue basis because of the difficulty in estimating the other components of GAAP... Read more
WASHINGTON –(BUSINESS WIRE)–Aug. 15, 2024– The Board of Directors of Xylem Inc. (NYSE: XYL), has declared a third quarter dividend of $0.36 per share payable on Sept. 26, 2024 , to shareholders of record as of Aug. 29, 2024 . About Xylem Xylem (XYL) is a Fortune 500 global water solutions Read more
Quarterly revenue of $887 million, at the high end of guidance Quarterly GAAP net income of $23 million and net income per share of $0.33 Quarterly Adjusted EBITDA of $228 million and Non-GAAP net earnings per diluted share of $1.53, exceeding the high-end of guidance ANDOVER, Mass., Aug. Read more
MENLO PARK, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2024. Second quarter results: Revenue of $36.0 million compared with $47.6 million in the prior-year period. Instrument revenue of $14.7 million compared with $29.9 million in the prior-year period. Instrument revenue in the... Read more
NovAliX is a drug discovery focused CRO with award-winning chemistry teams and one of the world’s most comprehensive biophysics platforms. Bruker and NovAliX intend to collaborate on enabling new paradigms in drug discovery, leveraging advanced biophysical methods, and NMR in particular, to structural, binding and functional characterization. STRASBOURG, France–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today... Read more
Q2 2024 revenues of $800.7 million, up 17.4% year-over-year (yoy); organic revenue up 7.4% yoy; CER revenue up 18.5% yoy Q2 2024 GAAP EPS $0.05; non-GAAP EPS $0.52, up 4.0% yoy Bruker increases FY 2024 revenue guidance to $3.38-$3.44 billion, now including the NanoString business; implies revenue growth of 14% to 16%, and organic revenue... Read more
Bruker Announces Date and Time of Second Quarter 2024 Earnings Release and Webcast BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2024 financial results before market opening on Tuesday, August 6, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the... Read more
Revenue of $2.2 billion , up 26% on a reported basis and 9% organically Earnings per share of $0.80 , up 78%; $1.09 on an adjusted basis, up 11% Raising full-year revenue guidance to $8.55 billion , up approximately 16%, with organic revenue growth of 5% to 6%, up from 4% to 6% Increasing full-year Read more